CD4+/CD56+ hematodermic tumor - The features of an evolving entity and its relationship to dendritic cells
CD4+/CD56+ hematodermic tumor - The features of an evolving entity and its relationship to dendritic cells
复制标题
DOI：
10.1309/fy6pk436nbk0ryd4
复制
发表时间：
2007-05-01
影响因子：
3.5
通讯作者：
Jones, Dan
中科院分区：
文献类型：
--
作者：
Herling, Marco;Jones, Dan
本文描述了各种肿瘤的诊断和分类的进展，这些肿瘤被称为母细胞性或胚胎性自然杀伤细胞淋巴瘤，CD4+/CD56+血液肿瘤，或浆细胞样树突状细胞系的肿瘤。正如提交给2005年血液病理学学会/欧洲血液病理学学会研讨会的病例所示，这些肿瘤表现出一系列的临床表现以及各种形态和免疫表型特征。最近的证据表明，在大多数情况下，组织发生与浆细胞样树突状细胞密切相关。我们概述了CD4+/CD56+血液皮肤肿瘤的典型表现特征和临床病程，包括白血病复发和向骨髓单核细胞分化的转变。目前未解决的问题在很大程度上与这一实体的局限性有关，特别是与髓系白血病和未分化母细胞肿瘤的关系，两者在诊断上存在重叠。尽管问题仍然存在，但对CD4+/CD56+血液肿瘤的描述及其改进的识别已经成为更好地了解血液系统恶性肿瘤的多系潜能的催化剂。
Described herein is the evolution in the diagnosis and classification of tumors that are variously known as blastic or blastoid natural killer cell lymphoma, CD4+/CD56+ hematodermic neoplasm, or tumors of plasmacytoid dendritic cell lineage. As illustrated by cases submitted to the 2005 Society for Hematopathology/European Association for Haematopathology Workshop, these tumors display a range of clinical manifestations and various morphologic and immunophenotypic features. Recent evidence suggests a close histogenetic relationship for most cases to plasmacytoid dendritic cells. We outline the typical presenting features and the clinical course of CD4+/CD56+ hematodermic tumors, including leukemic relapses with shifts to myelomonocytic differentiation. The currently unresolved issues are largely related to the limits of this entity, particularly the relationship to myeloid leukemia and undifferentiated blastic neoplasms, with which there is diagnostic overlap. Although questions remain, delineation of the CD4+/CD56+ hematodermic tumor and its improved recognition has already served as a catalyst toward better understanding of the multilineage potential of hematopoietic malignancies.